Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer
2022 San Antonio Breast Cancer Symposium
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate (ORR) of 68%. When combined with anastrozole, T-DXd led to a 58% ORR. This is the first trial to evaluate T-DXd in HER2-low breast cancer, a potentially curable disease (Abstract GS2-03).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The TRIO-US B-12 TALENT Clinical Trial was a study aimed to investigate the activity of TDXD, either alone or in combination with endocrine therapy in hormone receptor positive HER2 low breast cancer in the neoadjuvant or curative setting. So treating patients prior to surgery.
Why is this important? We know that patients with hormone receptor positive breast cancer treated with neoadjuvant therapy have a very low chance of achieving a pathologic complete response, and even a low chance of a good objective response to therapy, even with multi-agent chemotherapy or CDK-46 inhibitors and endocrine therapy we're not getting great outcomes.
TDXD has demonstrated significant benefits in the metastatic hormone receptor positive, HER2 low phase from the Destiny Breast 04 clinical trial, but has not yet been tested in the early stage setting in hormone receptor positive HER2 low disease. So we conducted a very early phase, phase two clinical trial where patients were treated with TDXD alone or with TDXD with anastrozole. Patients had to have stage two or three early stage breast cancer that was ER positive and had to have centrally confirmed HER2 low expression. We evaluated patients and then treated them with six cycles of TDXD, either alone or with anastrozole. And then after we enrolled about half the patients and began to see some near pathologic complete responses, we amended the protocol and extended the length of therapy to eight cycles.
We presented at San Antonio our interim data, very preliminary evidence of activity and our observations of how this drugs or drugs work together in this setting. We showed that there was an objective response rate of 68% with TDXD alone and 58% of TDXD plus endocrine therapy from baseline to the time of surgery. So this is an objective response rate. It's important to note the denominator includes patients who haven't yet completed therapy or who came off therapy early. This objective response rate is somewhat kind of like what we saw in the Destiny Breast 04 clinical trial. We also saw one patient have a pathologic complete response, and we saw an additional four patients have a near pathologic complete response in RCB one. So the data are very intriguing. We are still waiting for surgical results from 24% of the patients treated with TDXD and 31% of the patients treated in the combination arm. So it's too early to call a PATH CR rate. But the data that we got, it's very intriguing.
It's interesting, and it is allowing us to look at the biomarkers, what's happening to HER2? What's happening in the tumor microenvironment as we treat with TDXD, with or without endocrine therapy.
Next year, we plan to report the final results, and I think these results may help inform the design of studies of TDXD in the early stage setting for HER2 low disease.
Related Videos
The ASCO Post Staff
Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausal women with estrogen receptor (ER)-positive breast cancer reduces the risk of recurrence. OFS enables the use of adjuvant aromatase inhibitors as an alternative to tamoxifen, which can further reduce recurrence of ER-positive, HER2-negative disease. Very young women—those younger than 35 years old—should be considered for OFS, according to Dr. Francis. In addition, tamoxifen alone is appropriate in women with low-risk clinical-pathologic features.
The ASCO Post Staff
Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breast cancer with one to three involved lymph nodes and a recurrence score of ≤ 25 have worse outcomes than non-Hispanic White women. In addition, Black patients were more likely to accept treatment assignment than their White counterparts and were just as likely to remain on estrogen therapy at 6 and 12 months, suggesting that outcome differences may be less likely attributable to lack of treatment compliance within the first year (Abstract GS1-01 ).
The ASCO Post Staff
Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract PD1-08).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant (Abstract GS3-04).
The ASCO Post Staff
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for low levels of participation and advocates for capturing the experience of patients not represented in traditional clinical trials, so real-world data can address these validity deficits.
